Mammography has low risk of recall for false positive findings

August 23, 2004

A new long-term study finds over 20 years, only one in five women who have mammograms every two years will have to undergo follow up evaluation for a false positive finding. Only one in 16 will have an unnecessary invasive procedure over two decades. The study, published August 23, 2004 in the online edition of CANCER, a peer-reviewed journal of the American Cancer Society, should reassure physicians and patients that the risks of breast cancer screening are minimal given the notable benefit of breast cancer screening. The abstract of this article will be freely accessible via the CANCER Newsroom (http://www.interscience.wiley.com/cancer-newsroom) upon online publication.

Breast cancer screening by regular screening mammography has a proven benefit to saving lives. However, false positives and subsequent recall for follow up evaluation create significant psychosocial distress.

The extent of false positive recall is unclear. Previous studies have claimed the cumulative risk of a high false positive recall over the years was significant. However, the estimates and conclusions made to date are weakened by flawed study designs.

Solveig Hofvind, M.Sc., and her colleagues from the Cancer Registry of Norway reviewed data of 83,416 women from the Norwegian Breast Cancer Screening program, a uniform national program providing biennial screening mammography for women who are 50 to 69 years of age.

The authors found that women who begin biennial screening mammography at age 50 or 51 and participate in screening for 20 years had a cumulative 20-year risk for false positive recall of 20.8 percent. The risk for undergoing invasive procedures with benign findings was considerably lower at 6.2 percent. Most of those were for fine needle aspiration (3.9 percent). Only about one in 66 women had a core biopsy with benign findings (1.5 percent). Fewer than one in a hundred women had open biopsy with benign findings (0.9 percent).

Given this low 20-year risk level, conclude the authors, "all the estimates seem to be quite acceptable and ought to be communicated to the target group."

Article: "The Cumulative Risk of a False-Positive Recall in the Norwegian Breast Cancer Screening Program," Solveig Hofvind, Steinar Thoresen, Steinar Tretli, CANCER; Published Online: August 23, 2004 (DOI: 10.1002/cncr.20528); Print Issue Date: October 1, 2004.
-end-


Wiley

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.